Stockscreener 앱 받기
1.91
2.14%
0.04
시간 외 거래:
1.92
0.01
+0.52%
Gain Therapeutics Inc 주식(GANX)의 최신 뉴스
3 US Biotechs Developing Parkinson’s Therapies - Yahoo Finance
[ARS] Gain Therapeutics, Inc. SEC Filing - Stock Titan
[DEF 14A] Gain Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
GANX Technical Analysis | Trend, Signals & Chart Patterns | GAIN THERAPEUTICS INC (NASDAQ:GANX) - ChartMill
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026 - marketscreener.com
Gain Flat Ahead of Arizona Conference - Baystreet.ca
Gain Therapeutics, Inc. to Present Update on Parkinson’s Disease Drug GT-02287 at 3rd International GBA1 Meeting 2026 - Quiver Quantitative
Gain to present Parkinson’s drug update at Phoenix GBA1 meeting - Stock Titan
GANX Gain Therapeutics posts narrower Q4 2025 loss than estimates, but shares fall 2.39%.EPS Growth - Newser
GANX | Gain Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
Breakout Watch: Does Gain Therapeutics Inc have a sustainable dividendMarket Risk Analysis & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
GANX Should I Buy - Intellectia AI
Technical Analysis: Will Gain Therapeutics Inc benefit from green energy policiesQuarterly Trade Review & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Weekly Recap: Is Gain Therapeutics Inc a strong candidate for buy and holdMarket Sentiment Report & Real-Time Market Trend Scan - baoquankhu1.vn
Death Cross: Is Gain Therapeutics Inc attractive for institutional investorsPortfolio Value Report & Real-Time Stock Entry Alerts - baoquankhu1.vn
Stop Loss: What hedge funds are buying Gain Therapeutics IncInsider Selling & Long-Term Growth Stock Strategies - baoquankhu1.vn
Quarterly Trades: What hedge funds are buying Gain Therapeutics Inc2026 Spike Watch & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Gain Therapeutics Inc. (GANX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
GANX SEC FilingsGain Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
CTNM Stock Analysis: Contineum Therapeutics Inc posts 4.9 percent gain at 13.7 in recent trading - Newser
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Neumora Therapeutics, Inc. (NMRA) and Gain Therapeutics (GANX) - The Globe and Mail
HC Wainwright Has Positive Estimate for GANX Q1 Earnings - MarketBeat
Technical Analysis: What are Gain Therapeutics Incs growth levers2026 Momentum Check & Free High Return Stock Watch Alerts - baoquankhu1.vn
Published on: 2026-03-31 06:53:16 - baoquankhu1.vn
H.C. Wainwright reiterates Gain Therapeutics stock rating at buy By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Gain Therapeutics stock rating at buy - Investing.com
Aug Highlights: Is Gain Therapeutics Inc part of any major index2026 Market WrapUp & Daily Growth Stock Tips - baoquankhu1.vn
Analysts Are Bullish on These Healthcare Stocks: Gain Therapeutics (GANX), CG Oncology, Inc. (CGON) - The Globe and Mail
CEO Moves: Is Gain Therapeutics Inc being accumulated by smart money2026 Support & Resistance & Safe Capital Investment Plans - baoquankhu1.vn
Recap Report: What is Gain Therapeutics Incs 5 year growth outlookProduct Launch & Safe Entry Zone Identification - baoquankhu1.vn
Gain Therapeutics (NASDAQ: GANX) grants 50,000 stock options to officer - Stock Titan
Gain Therapeutics (NASDAQ:GANX) Issues Earnings Results - marketbeat.com
Gain Therapeutics 10-K: $(0.61) EPS; $20.8M cash; net loss $(20.16)M - TradingView
Gain Therapeutics reports $20.2M net loss, $20.8M cash at year-end 2025 - TradingView
[10-K] Gain Therapeutics, Inc. Files Annual Report - Stock Titan
Gain Therapeutics (NASDAQ: GANX) 2025 loss narrows as cash doubles - Stock Titan
Gain Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update - Bitget
Gain says its Parkinson’s drug is on track for Phase 2 by 3Q26 - Stock Titan
Gain Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
GANX: Disease-modifying Parkinson's therapy advances to phase II with strong biomarker support - TradingView
Gain Therapeutics Highlights GT-02287 Biomarker Signals, Eyes Phase 2 Start in Q3 at Roth Conference - MarketBeat
Parkinson’s therapy shows promise for motor function: Trial data - Parkinson's News Today
Gain Therapeutics Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Aug Volume: Is RDFN stock a buy or sell2026 Market Overview & Verified Momentum Stock Alerts - baoquankhu1.vn
Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Gain Therapeutics (GANX) - The Globe and Mail
Market Moves: What hedge funds are buying Gain Therapeutics IncWeekly Gains Report & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Published on: 2026-03-21 10:38:36 - baoquankhu1.vn
Gain Therapeutics to Present at the 38th Annual ROTH Conference - The Manila Times
1.77%
0.25%
자본화:
|
볼륨(24시간):